Gastric cancer
Conditions
Interventions
mFOLFOX6
Sponsors
Aichi Cancer Center Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically confirmed adenocarcinoma of gastric or esophagogastric junction. 2) Presence of inoperable recurrent or metastatic disease. 3) Received fluoropirimidines, cisplatin and either taxanes and irinotecan before as anticancer treatment for advanced gastric cancer. 4) Male or female patients >=20 years old at the time of informed consent. 5) ECOG performance status of 0 or 1. 6) Presence of at least one measurable disease as defined by RECIST version 1.1. 7) Written informed consent.
Exclusion criteria
Exclusion criteria: 1) Patients with symptomatic brain metastases. 2) Requires perodial drainage of pleural fluid, ascites or pericardial effusion. 3) Received chemotherapy, radiotherapy, surgical or any other experimental therapies as anticancer treatment within 14 days before the first administration of this trial. 4) Previous treatment with oxaliplatin. 5) Concurrent uncontrolled medical condition including active infection, hypertension, diabetes mellitus, pulmonary, cardiac or psychiatric disease 5) known or suspected of not being able to comply with this trial protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate assessed by independent review committee | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate, progression free survival, overall survival, adverse events, quality of life | — |
Countries
Japan
Contacts
Public ContactSeiichiro Mitani
Aichi Cancer Center Hospital Department of Clinical Oncology
Outcome results
None listed